By Improving the Accuracy of Tumor Grading, MapQuant Dx(TM) Genomic Grade
Could Spare Tens of Thousands Chemotherapy Treatments per Year
ASCO Annual Meeting, May 30, 2008 - booth 23128
CHICAGO, May 30 /PRNewswire/ -- Ipsogen SA (Marseilles, France and New Haven, CT, USA), a cancer profiler that markets molecular diagnostic assays for leukaemia announced today that it is entering the breast cancer diagnostic market with the European launch of MapQuant Dx(TM) Genomic Grade. MapQuant Dx(TM) Genomic Grade is the very first molecular diagnostic test to accurately measure tumor grade, a consensus indicator of tumor proliferation, risk of metastasis and response to chemotherapy.
Histological tumor grading is considered a decision factor in most national and international guidelines to breast cancer treatment. While it is generally recommended to treat high-grade "grade 3" breast carcinoma with chemotherapy because they are chemosensitive and will often recur otherwise. By contrast, most low-grade "grade 1" tumors should not be treated with chemotherapy because they have a good prognosis and are often chemo-insensitive.
A key clinical issue is how to treat the 50% of breast cancers tested today as uncertain/intermediate "grade 2" by current methods - based on the visual examination of tumor sections under the microscope.
MapQuant Dx(TM) Genomic Grade test directly measures the expression of the 97 genes that best characterize high-grade vs. low-grade tumors. It can resolve these "grade 2" tumors into either "grade 1" or "grade 3" tumors in 80 % of cases.
MapQuant Dx(TM) Genomic Grade test is especially useful when tumor grade information can be decisive for prescribing a chemotherapy. According to most guidelines, this is the case for hormone-sensitive (ER+) node-negative (N-) invasive breast carcinoma.
"In these patients, most grade 2 tumors are treated by chemotherapy and
hormonotherapy. It is expected
|SOURCE Ipsogen SA|
Copyright©2008 PR Newswire.
All rights reserved